- Home
- ALGS vs VERU Comparison
ALGS vs VERU Comparison
Compare ALGS & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALGS | VERU |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0M | 41.7M |
| IPO Year | 2020 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ALGS | VERU |
|---|---|---|
| Price | $7.74 | $2.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $46.67 | $22.50 |
| AVG Volume (30 Days) | 31.7K | ★ 53.2K |
| Earning Date | 06-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 88.30 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,186,000.00 | ★ $16,296,958.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.76 | $0.36 |
| 52 Week High | $13.69 | $4.59 |
Technical Indicators
Market Signals| Indicator | ALGS | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 56.23 | 44.41 |
| Support Level | $7.61 | $2.15 |
| Resistance Level | $8.84 | $2.77 |
| Average True Range (ATR) | 0.55 | 0.14 |
| MACD | 0.15 | -0.01 |
| Stochastic Oscillator | 85.21 | 11.76 |
Price Performance
Historical ComparisonAbout ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About VERU Veru Inc.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.